Answers are grounded in this paper and cite their sources.
Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF), which is used to treat several cancers. Currently, experience with anti-VEGF treatment for psoriasis is limited, and no published reports on this use exist. We describe a patient with metastatic colon cancer and psoriasis who experienced complete remission of psoriasis during treatment with bevacizumab and combination chemotherapy without any other treatment for psoriasis. These data suggest that bevacizumab may be a promising therapeutic agent for the treatment of psoriasis.
No takes yet. Share an insight, caveat, or question.
Akman et al. (2008) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: